Page 132 - 《中国药房》2025年6期

tinib for pulmonary arterial hypertension[J]. Pulm Circ， [13] KIMURA G，KATAOKA M，INAMI T，et al. Sorafenib as
2024，14（1）：e12352. a potential strategy for refractory pulmonary arterial hy‐
[ 2 ] HUMBERT M，KOVACS G，HOEPER M M，et al. 2022 pertension[J]. Pulm Pharmacol Ther，2017，44：46-49.
ESC/ERS guidelines for the diagnosis and treatment of [14] VEEROJU S，KOJONAZAROV B，WEISS A，et al.
pulmonary hypertension[J]. Eur Heart J，2022，43（38）： Therapeutic potential of regorafenib：a multikinase inhibi‐
3618-3731. tor in pulmonary hypertension[J]. Int J Mol Sci，2021，22
[ 3 ] ZOLTY R. Pulmonary arterial hypertension specific （3）：1502.
therapy：the old and the new[J]. Pharmacol Ther，2020， [15] SHIMAUCHI T，BOUCHERAT O，YOKOKAWA T，et
214：107576. al. PARP1-PKM2 axis mediates right ventricular failure
[ 4 ] ALKHATIB Y，ALBASHAIREH D，AL-AQTASH T，et associated with pulmonary arterial hypertension[J]. JACC
al. The role of tyrosine kinase inhibitor “lapatinib” in pul‐ Basic Transl Sci，2022，7（4）：384-403.
monary hypertension[J]. Pulm Pharmacol Ther，2016，37： [16] WEISS A，NEUBAUER M C，YERABOLU D，et al. Tar‐
81-84. geting cyclin-dependent kinases for the treatment of pul‐
[ 5 ] 国家卫生健康委. 新型抗肿瘤药物临床应用指导原则： monary arterial hypertension[J]. Nat Commun，2019，10
2023 年 版 [EB/OL].（2024-01-03）[2024-08-21]. http：// （1）：2204.
www.nhc.gov.cn/yzygj/s7659/202401/48be6030a029446- [17] BABICHEVA A，MAKINO A，YUAN J X. mTOR signa-
c93b852bfd4a5fdf6.shtml. ling in pulmonary vascular disease：pathogenic role and
National Health Commission. Clinical application guide‐ therapeutic target[J]. Int J Mol Sci，2021，22（4）：2144.
lines for novel antitumor drugs：2023 edition[EB/OL]. [18] SEYFARTH H J，STEFAN H，HALANK M，et al. Everoli‐
（2024-01-03）[2024-08-21]. http：//www.nhc.gov.cn/yzygj/ mus in patients with severe pulmonary hypertension：a
s7659/202401/48be6030a029446c93b852bfd4a5fdf6.shtml. safety and efficacy pilot trial[J]. Pulm Circ，2013，3（3）：
[ 6 ] WEATHERALD J，BONDEELLE L，CHAUMAIS M C， 632-638.
et al. Pulmonary complications of Bcr-Abl tyrosine kinase [19] ZAMANIAN R T，BADESCH D，CHUNG L，et al.
inhibitors[J]. Eur Respir J，2020，56（4）：2000279. Safety and efficacy of B-cell depletion with rituximab for
[ 7 ] FALZONE L，SALOMONE S，LIBRA M. Evolution of the treatment of systemic sclerosis-associated pulmonary
cancer pharmacological treatments at the turn of the third arterial hypertension：a multicenter，double-blind，rando-
millennium[J]. Front Pharmacol，2018，9：1300. mized，placebo-controlled trial[J]. Am J Respir Crit Care
[ 8 ] SHAH A J，BECKMANN T，VORLA M，et al. New drugs Med，2021，204（2）：209-221.
and therapies in pulmonary arterial hypertension[J]. Int J [20] BENZA R L，MILLER D P，BARST R J，et al. An evalua‐
Mol Sci，2023，24（6）：5850. tion of long-term survival from time of diagnosis in pul‐
[ 9 ] HOEPER M M，BARST R J，BOURGE R C，et al. Ima‐ monary arterial hypertension from the REVEAL Registry
tinib mesylate as add-on therapy for pulmonary arterial hy‐ [J]. Chest，2012，142（2）：448-456.
pertension：results of the randomized IMPRES study[J]. [21] TAMURA Y，TAMURA Y. Dasatinib-induced pulmonary
Circulation，2013，127（10）：1128-1138. hypertension[J]. Intern Med，2022，61（15）：2245-2246.
[10] BHOLA K D，TEODORA C，ALEKSANDRA T，et al. [22] GÜRDOĞAN M，DEMIR M，YALTA K，et al. Cancer
Role of epidermal growth factor inhibition in experimen‐ therapy-related pulmonary hypertension：a review of
tal pulmonary hypertension[J]. Am J Respir Crit Care mechanisms and implications for clinical practice[J]. Ana‐
Med，2010，181（2）：158-167. tol J Cardiol，2023，27（6）：299-307.
[11] YUX F，ZHAOX J，ZHANGJ T，et al. Dacomitinib，a new [23] YO S，THENGANATT J，LIPTON J，et al. Incident pul‐
pan-EGFR inhibitor，is effective in attenuating pulmonary monary arterial hypertension associated with bosutinib[J].
vascular remodeling and pulmonary hypertension[J]. Eur J Pulm Circ，2020，10（3）：2045894020936913.
Pharmacol，2019，850：97-108. [24] LEIVA O，BEATY W，SOO S，et al. Cancer therapy-
[12] PENG L Y，YU M，YANG M X，et al. Icotinib attenuates associated pulmonary hypertension and right ventricular
monocrotaline-induced pulmonary hypertension by pre‐ dysfunction：etiologies and prognostic implications[J].
venting pulmonary arterial smooth muscle cell dysfunction Rev Cardiovasc Med，2024，25（3）：87.
[J]. Am J Hypertens，2020，33（8）：775-783. [25] TABBÒ F，AVENI AD'，TOTA D，et al. Pulmonary arte‐

· 762 · China Pharmacy 2025 Vol. 36 No. 6 中国药房 2025年第36卷第6期